Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 8, 2017, Pages

  Shields, Ryan K ^a,b   Nguyen, M Hong ^a,b   Chen, Liang ^c   Press, Ellen G ^a   Potoski, Brian A ^a,b,d   Marini, Rachel V ^b   Doi, Yohei ^a,b   Kreiswirth, Barry N ^c   Clancy, Cornelius J ^a,b,e  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c RUTGERS UNIVERSITY   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Bacteremia; Carbapenem resistant Enterobacteriaceae; Ceftazidime avibactam; Clinical success; Klebsiella pneumoniae; Klebsiella pneumoniae carbapenemase

Indexed keywords

AMINOGLYCOSIDE; AVIBACTAM PLUS CEFTAZIDIME; CARBAPENEM; COLISTIN; GENTAMICIN; MEROPENEM; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; BACTERIAL PROTEIN; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CARBAPENEMASE; CEFTAZIDIME;

ACUTE KIDNEY FAILURE; ADULT; AGED; APACHE; ARTICLE; BACTEREMIA; BLOOD CULTURE; BROTH DILUTION; DISEASE SEVERITY; ENTEROBACTERIACEAE INFECTION; FEMALE; HUMAN; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE INFECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORTALITY RATE; NEPHROTOXICITY; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; DRUG EFFECTS; ISOLATION AND PURIFICATION; KLEBSIELLA INFECTION; KLEBSIELLA PNEUMONIAE; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BACTEREMIA; BACTERIAL PROTEINS; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; CARBAPENEMS; CEFTAZIDIME; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 85026380424     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00883-17     Document Type: Article

References (12)

1. Centers for Disease Control and Prevention. 2016. Healthcare-associated infections (HAIs): FAQs about choosing and implementing a CRE definition. https://www.cdc.gov/hai/organisms/cre/definition.html. Accessed 6 April 6.
2. Daikos GL, Tsaousi S, Tzouvelekis LS, Anyfantis I, Psichogiou M, Argyropoulou A, Stefanou I, Sypsa V, Miriagou V, Nepka M, Georgiadou S, Markogiannakis A, Goukos D, Skoutelis A. 2014. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 58:2322–2328. https://doi.org/10.1128/AAC.02166-13.
3. Tzouvelekis LS, Markogiannakis A, Piperaki E, Souli M, Daikos GL. 2014. Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect 20:862–872. https://doi.org/10.1111/1469-0691.12697.
4. Clancy CJ, Chen L, Hong JH, Cheng S, Hao B, Shields RK, Farrell AN, Doi Y, Zhao Y, Perlin DS, Kreiswirth BN, Nguyen MH. 2013. Mutations of the ompK36 porin gene and promoter impact responses of sequence type 258, KPC-2-producing Klebsiella pneumoniae strains to doripenem and doripenem-colistin. Antimicrob Agents Chemother 57:5258–5265. https://doi.org/10.1128/AAC.01069-13.
5. Clancy CJ, Chen L, Shields RK, Zhao Y, Cheng S, Chavda KD, Hao B, Hong JH, Doi Y, Kwak EJ, Silveira FP, Abdel-Massih R, Bogdanovich T, Humar A, Perlin DS, Kreiswirth BN, Hong Nguyen M. 2013. Epidemiology and molecular characterization of bacteremia due to carbapenem-resistant Klebsiella pneumoniae in transplant recipients. Am J Transplant 13: 2619–2633. https://doi.org/10.1111/ajt.12424.
6. Temkin E, Torre-Cisneros J, Beovic B, Benito N, Giannella M, Gilarranz R, Jeremiah C, Loeches B, Machuca I, Jimenez-Martin MJ, Martinez JA, Mora-Rillo M, Navas E, Osthoff M, Pozo JC, Ramos Ramos JC, Rodriguez M, Sanchez-Garcia M, Viale P, Wolff M, Carmeli Y. 2017. Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms. Antimicrob Agents Chemother 61:e01964-16. https://doi.org/10.1128/AAC.01964-16.
7. Shields RK, Potoski BA, Haidar G, Hao B, Doi Y, Chen L, Press EG, Kreiswirth BN, Clancy CJ, Nguyen MH. 2016. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis 63:1615–1618. https://doi.org/10.1093/cid/ciw636.
8. King M, Heil E, Kuriakose S, Bias T, Huang V, El-Beyrouty C, McCoy D, Hiles J, Richards L, Gardner J, Harrington N, Biason K, Gallagher JC. 2016. Outcomes of ceftazidime/avibactam in patients with carbapenem-resistant Enterobacteriaceae (CRE) infections: a multi-center study, abstr. 2034. Abstr ID Week 2016.
9. Wu G, Abraham T, Lee S. 2016. ceftazidime-avibactam for treatment of carbapenem-resistant Enterobacteriaceae bacteremia. Clin Infect Dis 63: 1147–1148. https://doi.org/10.1093/cid/ciw491.
10. Tumbarello M, Trecarichi EM, De Rosa FG, Giannella M, Giacobbe DR, Bassetti M, Losito AR, Bartoletti M, Del Bono V, Corcione S, Maiuro G, Tedeschi S, Celani L, Cardellino CS, Spanu T, Marchese A, Ambretti S, Cauda R, Viscoli C, Viale P, Isgri S. 2015. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother 70:2133–2143. https://doi.org/10.1093/jac/dkv086.
11. Satlin MJ, Chen L, Patel G, Gomez-Simmonds A, Weston G, Kim AC, Seo SK, Rosenthal ME, Sperber SJ, Jenkins SG, Hamula CL, Uhlemann AC, Levi MH, Fries BC, Tang YW, Juretschko S, Rojtman AD, Hong T, Mathema B, Jacobs MR, Walsh TJ, Bonomo RA, Kreiswirth BN. 2017. Multicenter clinical and molecular epidemiological analysis of bacteremia due to carbapenem-resistant Enterobacteriaceae (CRE) in the CRE epicenter of the United States. Antimicrob Agents Chemother 61:e02349-16. https://doi.org/10.1128/AAC.02349-16.
12. KPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother 61:e02097-16. https://doi.org/10.1128/AAC.02097-16.